FDA Renews CTGTAC Charter

October 14, 2026

The Food and Drug Administration has renewed the charter for the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) through Oct. 28, 2028. The CTGTAC reviews and evaluates data related to the safety, effectiveness and appropriate use of human cells, human tissues, gene transfer therapies and xenotransplantation products that are intended for transplantation, implantation, infusion, and transfer to prevent or treat of a broad spectrum of human diseases.